Funding Received
$310 Million in 3 Rounds from 4 Investors
Most Recent Funding
$134 Million Series B on August 5, 2014
Headquarters:
Seattle, WA
Description:
Juno Therapeutics, a clinical-stage company, develops immunotherapies for the treatment of cancer.
Founders:
Michael Jensen, Michel Sadelain, Isabelle Rivière, Stan Riddell, Phil Greenberg, Renier Brentjens
Categories:
Health and Wellness, Health Care, Biotechnology
Website:
http://junotherapeutics.com

Company Details

Update

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Current Team (7)

Update

Funding Rounds (3) - $310M

Update

Board Members and Advisors (8)

Update

Investors (4)

Update
  • Tyd2bpo9alshsclbabyv

    Bezos Expeditions

    Bezos Expeditions manages Jeff Bezos' personal venture capital investments.
  • Ficyggtwmdgziyl2exmj

    Venrock

    Venrock is a venture capital firm investing in technology and healthcare companies.
  • 920ef1c9e2d2a1b871893ee51107f97c

    ARCH Venture Partners

    ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs,...
  • Bf406bac7e926f8f586f1e8886b53535

    Alaska Permanent Fund

    The Alaska Permanent Fund is a constitutionally established permanent fund managed by a...

Offices/Locations (1)

Update
  • Office

    307 Westlake Avenue North

    Seattle

    Seattle, WA 98109

    USA

Images (1)

Update
  • Bfe0f46a1a477507a07b83c8e94685ad